Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07238283 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 3
Started2025-12-02
View on ClinicalTrials.gov ↗

Amendment history

2025-12-02
Not Yet Recruiting→Recruiting Study Status, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-12→confirmed 2025-12-02
Study sitesdetails revised at 1 of 1 site
2025-11-18
Original filing
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus nab-paclitaxel combined with gemcitabine as first-line treatment for advanced pancreatic cancer.
Trial Details
NCT Number NCT07238283
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions First-line Treatment of Metastatic Pancreatic Cancer
Enrollment 662 participants
Start Date 2025-12-02
Primary Completion 2028-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-09